Correlation Between Access Blood Flow and Extracorporeal Blood Flow
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00522704
Recruitment Status : Unknown
Verified November 2014 by FRANKLIN MORA, Instituto Nacional de Cardiologia Ignacio Chavez. Recruitment status was: Recruiting
First Posted : August 30, 2007
Last Update Posted : November 6, 2014
Instituto Nacional de Cardiologia Ignacio Chavez
JOSE CARRASCO ARTEAGA HOSPITAL FROM Ecuadorian Institute of Social Security
Information provided by (Responsible Party):
FRANKLIN MORA, Instituto Nacional de Cardiologia Ignacio Chavez
The purpose of this study is to determine if Effective Extracorporeal Blood Flow(eEBF) has correlation with Access Blood Flow (Qa), when eEBF adjusts with Dynamic Arterial Line Pressure (DALP) in patients with Arteriovenous fistulae in hemodialysis treatment.
Condition or disease
Other: Dynamic Arterial line Pressure (DALP)
Accesses that show a large (>15%) decrement over time in vascular access blood flow are associated with a high risk of thrombosis. Serial measurements of vascular access blood flow predict access thrombosis. At the moment, the measurement of access flow is time consuming, operator dependent, so that it cannot be done with every treatment. We hypothesized that extracorporeal blood flow at pressure of -200 to -260 mmHg in arterial line has correlation with access blood flow and this can be used to estimate access blood flow.
eEBF will be record with dynamic arterial line pressure of -60 mmHg (eEBF-60 mmHg), -100 mmHg (eEBF-100 mmHg), -160 mmHg (eEBF-160 mmHg), -200 mmHg (eEBF-200 mmHg) and -260 mmHg (eEBF-260 mmHg) during the first one half hour of the dialysis session. Access Blood flow will be performed with blood thermal monitor.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with Chronic Kidney Dissease K-DIGO 5d in hemodialysis.
Patients with Chronic Kidney Disease K-DIGO 5d in hemodialysis treatment)
Permanent vascular accesses with native arteriovenous fistulas (AVF)